Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alebund Raises $60 Million for China Development of Novel Renal Drugs

publication date: May 10, 2021

Alebund Pharma, a Shanghai company developing renal disease therapies, raised $60 million in a Series B round led by Quan Capital. The company's small-molecule/biologic candidates target chronic kidney disease/dialysis complications, IgA nephropathy, diabetic kidney disease and autosomal dominant polycystic kidney disease (ADPKD). The company's lead product is the ADPKD candidate, which is currently in a Phase II trial. It will use the proceeds from the financing to build a manufacturing site plus R&D of its portfolio. Alebund said it is the first China biopharma to focus exclusively on renal disease. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital